Ardelyx Inc. (ARDX)
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story
Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force to convert demand into realized revenue.
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ardelyx Q2 Earnings Call Highlights
Ardelyx NASDAQ: ARDX reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company's largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased payer restrictions affecting patient access to IBSRELA.
New Strong Sell Stocks for July 29th
ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability.
Ardelyx: Low Price, But High Implied Valuation
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
Ardelyx (ARDX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
